-
1
-
-
67651210632
-
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
-
Emerging Risk Factors Collaboration
-
Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302: 412-423.
-
(2009)
JAMA
, vol.302
, pp. 412-423
-
-
-
2
-
-
84870059868
-
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The epic-norfolk prospective population study
-
Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32:3058-3065.
-
(2012)
Arterioscler Thromb Vasc Biol
, vol.32
, pp. 3058-3065
-
-
Gurdasani, D.1
Sjouke, B.2
Tsimikas, S.3
Hovingh, G.K.4
Luben, R.N.5
Wainwright, N.W.6
Pomilla, C.7
Wareham, N.J.8
Khaw, K.T.9
Boekholdt, S.M.10
Sandhu, M.S.11
-
3
-
-
77954312278
-
Lipoprotein(a) and ischemic heart disease - A causal association? A review
-
Kamstrup PR. Lipoprotein(a) and ischemic heart disease-a causal association? A review. Atherosclerosis. 2010;211:15-23.
-
(2010)
Atherosclerosis
, vol.211
, pp. 15-23
-
-
Kamstrup, P.R.1
-
4
-
-
78649888517
-
European atherosclerosis society consensus panel. Lipoprotein(a) as a cardiovascular risk factor: Current status
-
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
-
(2010)
Eur Heart J
, vol.31
, pp. 2844-2853
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Ray, K.3
Borén, J.4
Andreotti, F.5
Watts, G.F.6
Ginsberg, H.7
Amarenco, P.8
Catapano, A.9
Descamps, O.S.10
Fisher, E.11
Kovanen, P.T.12
Kuivenhoven, J.A.13
Lesnik, P.14
Masana, L.15
Reiner, Z.16
Taskinen, M.R.17
Tokgözoglu, L.18
Tybjærg-Hansen, A.19
-
5
-
-
80054814637
-
Oxidized phospholipids on apob-100-containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events
-
Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011;5:673-694.
-
(2011)
Biomark Med
, vol.5
, pp. 673-694
-
-
Taleb, A.1
Witztum, J.L.2
Tsimikas, S.3
-
6
-
-
73549097512
-
Genetic variants associated with lp(a) lipoprotein level and coronary disease
-
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.
-
(2009)
N Engl J Med
, vol.361
, pp. 2518-2528
-
-
Clarke, R.1
Peden, J.F.2
Hopewell, J.C.3
Kyriakou, T.4
Goel, A.5
Heath, S.C.6
Parish, S.7
Barlera, S.8
Franzosi, M.G.9
Rust, S.10
Bennett, D.11
Silveira, A.12
Malarstig, A.13
Green, F.R.14
Lathrop, M.15
Gigante, B.16
Leander, K.17
De Faire, U.18
Seedorf, U.19
Hamsten, A.20
Collins, R.21
Watkins, H.22
Farrall, M.23
Procardis, C.24
more..
-
7
-
-
74749107585
-
Efficacy criteria and cholesterol targets for ldl apheresis
-
Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandry P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208:317-321.
-
(2010)
Atherosclerosis
, vol.208
, pp. 317-321
-
-
Thompson, G.R.1
Barbir, M.2
Davies, D.3
Dobral, P.4
Gesinde, M.5
Livingston, M.6
Mandry, P.7
Marais, A.D.8
Matthews, S.9
Neuwirth, C.10
Pottle, A.11
Le Roux, C.12
Scullard, D.13
Tyler, C.14
Watkins, S.15
-
8
-
-
84872193917
-
German apheresis working group. Current view: Indications for extracorporeal lipid apheresis treatment
-
Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E; German Apheresis Working Group. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl. 2012;7(suppl 1):15-19.
-
(2012)
Clin Res Cardiol Suppl
, vol.7
, Issue.SUPPL. 1
, pp. 15-19
-
-
Schettler, V.1
Neumann, C.L.2
Hulpke-Wette, M.3
Hagenah, G.C.4
Schulz, E.G.5
Wieland, E.6
-
9
-
-
84890903024
-
Publication of a decision of federal joint committee on apheresis for isolated lp(a) elevation with progressive cardiovascular disease
-
German Federal Ministry of Health
-
German Federal Ministry of Health. Publication of a decision of Federal Joint Committee on apheresis for isolated Lp(a)-elevation with progressive cardiovascular disease. Transactions of the German Federal Ministries (BAnz). 2008; 138: 3321.
-
(2008)
Transactions of the German Federal Ministries (BAnz)
, vol.138
, pp. 3321
-
-
-
10
-
-
61549101898
-
Group of clinical investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
-
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D; Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229-239.
-
(2009)
Nat Clin Pract Cardiovasc Med
, vol.6
, pp. 229-239
-
-
Jaeger, B.R.1
Richter, Y.2
Nagel, D.3
Heigl, F.4
Vogt, A.5
Roeseler, E.6
Parhofer, K.7
Ramlow, W.8
Koch, M.9
Utermann, G.10
Labarrere, C.A.11
Seidel, D.12
-
11
-
-
0033811877
-
The rebound of lipoproteins after ldl-apheresis. Kinetics and estimation of mean lipoprotein levels
-
Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152:519-526.
-
(2000)
Atherosclerosis
, vol.152
, pp. 519-526
-
-
Kroon, A.A.1
Van't Hof, M.A.2
Demacker, P.N.3
Stalenhoef, A.F.4
-
12
-
-
44149123549
-
Heart-uk ldl apheresis working group. Recommendations for the use of ldl apheresis
-
Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247-255.
-
(2008)
Atherosclerosis
, vol.198
, pp. 247-255
-
-
Thompson, G.R.1
-
13
-
-
0023636242
-
Cdna sequence of human apolipoprotein(a) is homologous to plasminogen
-
McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
-
(1987)
Nature
, vol.330
, pp. 132-137
-
-
McLean, J.W.1
Tomlinson, J.E.2
Kuang, W.J.3
Eaton, D.L.4
Chen, E.Y.5
Fless, G.M.6
Scanu, A.M.7
Lawn, R.M.8
-
14
-
-
79952792964
-
Heart protection study collaborative group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the heart protection study
-
Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R; Heart Protection Study Collaborative Group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011;4:68-73.
-
(2011)
Circ Cardiovasc Genet
, vol.4
, pp. 68-73
-
-
Hopewell, J.C.1
Clarke, R.2
Parish, S.3
Armitage, J.4
Lathrop, M.5
Hager, J.6
Collins, R.7
-
15
-
-
84873501705
-
-
KBVAnnual quality report 2011 and 2012. (in German). Accessed August 30, 2013
-
National Association of Statutory Health Insurance Physicians. KBVAnnual quality report 2011 and 2012. http://www.kbv.de/presse/6793.html (in German). Accessed August 30, 2013.
-
National Association of Statutory Health Insurance Physicians
-
-
|